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Human narcolepsy with cataplexy is a neurological disorder, which develops due to a deficiency in hypocretin producing neurons
in the hypothalamus. There is a strong association with human leucocyte antigens HLA-DR2 and HLA-DQB1*0602. The disease
typically starts in adolescence. Recent developments in narcolepsy research support the hypothesis of narcolepsy being an
immune-mediated disease. Narcolepsy is associated with polymorphisms of the genes encoding T cell receptor alpha chain,
tumour necrosis factor alpha and tumour necrosis factor receptor II. Moreover the rate of streptococcal infection is increased at
onset of narcolepsy. The hallmarks of anti-self reactions in the tissue—namely upregulation of major histocompatibility antigens
and lymphocyte infiltrates—are missing in the hypothalamus. These findings are questionable because they were obtained by
analyses performed many years after onset of disease. In some patients with narcolepsy autoantibodies to Tribbles homolog 2,
which is expressed by hypocretin neurons, have been detected recently. Immune-mediated destruction of hypocretin producing
neurons may be mediated by microglia/macrophages that become activated either by autoantigen specific CD4+ T cells or
superantigen stimulated CD8+ T cells, or independent of T cells by activation of DQB1*0602 signalling. Activation of microglia
and macrophages may lead to the release of neurotoxic molecules such as quinolinic acid, which has been shown to cause
selective destruction of hypocretin neurons in the hypothalamus.
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Introduction
Narcolepsy with cataplexy—a sudden, short loss of muscle tone
triggered by emotions—is a disabling chronic brain disorder
characterized by excessive daytime sleepiness, sleep paralysis,
hallucinations and disturbed nocturnal sleep. Although the severity
of daytime sleepiness is fluctuating, it is present most of the time.
Daytime sleepiness ranges from mild sleepiness that is easily over-
come to excessive overwhelming and irresistible daytime sleepi-
ness. The latter may manifest itself by episodes of daytime sleep
occurring without warning (‘sleep attacks’) (Dement et al., 1976;
Bassetti and Aldrich, 1996). The prevalence of narcolepsy with
cataplexy falls between 25 and 50 per 100 000 people
(Longstreth et al., 2007). There seems to be a slight male
predominance. Age at onset is between 15 and 40 years in
most cases.
Up to 95% of patients with narcolepsy and cataplexy have low
CSF hypocretin-1 levels (Nishino et al., 2000; Baumann and
Bassetti, 2005; Bourgin et al., 2008). Autoptic data suggest that
this deficiency reflects a loss of hypothalamic neurons which
produce hypocretin peptides (hypocretin-1 and hypocretin-2;
also known as orexins A and B) (Thannickal et al., 2000), which
in turn bind to hypocretin receptors (hypocretin receptor-1 and
hypocretin receptor-2). The hypocretin system in sleep, wakeful-
ness and narcolepsy has been discussed in detail elsewhere (for
review see Sakurai, 2007). In brief, two independent studies in
1999 showed that mutations in the hypocretin-2 receptor gene
are responsible for canine narcolepsy-cataplexy and a gene
deletion of hypocretin in mice leads to a phenotype strikingly
similar to human narcolepsy (Chemelli et al., 1999; Lin et al.,
1999). Hypocretin-1 and hypocretin-2, which are derived from a
common precursor peptide, the prepro-orexin, share significant
homology in their C-terminal part. Hypocretin-1 binds to two G
protein-coupled receptors named hypocretin receptor-1 and -2.
Whereas the latter is a non-selective receptor for both peptides,
hypocretin receptor-1 is selective for hypocretin-1. Both
hypocretin-1 and -2 are exclusively produced in the lateral
hypothalamic area; their respective receptors are expressed in
the entire CNS. In regard to the narcolepsy-like phenotype in
animals with non-functional hypocretin or hypocretin receptor
genes it is remarkable that hypocretin-1 and -2 increase wake
time and decreased rapid eye movement and non-rapid eye move-
ment sleep time. The inability to maintain wakefulness seems to
depend critically upon hypocretin-2, while the profound dysregu-
lation of rapid eye movement sleep control emerges from loss of
signalling through both hypocretin receptor-1 and hypocretin
receptor-2-dependent pathways (Willie et al., 2003); for review
see Ohno and Sakurai (2008).
In humans, only one patient with an early onset of disease in
childhood has been reported to have a mutation in the hypocretin
gene (Peyron et al., 2000). The aetiology of the reduction in the
number of neurons containing detectable pro-hypocretin mRNA or
hypocretin-like immunoreactivity in the hypothalamus in narco-
lepsy remains unexplained. Low hypocretin concentrations in the
CNS may point to a failure of the neurons to produce hypocretin.
In the normal hypothalamus, 80% of the hypocretin-producing
neurons also express prodynorphin and neuronal activity-regulated
pentraxin. The number of neurons expressing these gene products
is reduced in proportion to the loss of hypocretin neurons (Blouin
et al., 2005; Crocker et al., 2005). The selectivity of the loss
of hypocretin neurons in the hypothalamus is shown by the
absence of reduction in the number of neurons expressing
melanin-concentrating hormone (Thannickal et al., 2009). In this
review we will focus on immunological mechanisms possibly
involved in the pathophysiology of the disease.
Why should narcolepsy
have anything to do with
immunology? It is the
association with HLA-DR2
genes and a newly discovered
T cell receptor alpha
polymorphism
Narcolepsy is genetically characterized by strong linkage to distinct
human leucocyte antigen (HLA) alleles. A genetic association of
narcolepsy with HLA-DR2 and HLA-DQ1 in the major histocom-
patibility (MHC) region was described more than 20 years ago
(Langdon et al., 1984). High resolution typing by DNA techniques
has further characterized the DR2 and DQ1 serological specificities
associated with narcolepsy. As reviewed recently, the association
between HLA class II genes and narcolepsy was present in all
ethnic groups and the most tightly linked HLA allele was
DQB1*0602 (Tafti, 2009). Whereas this allele is present in only
12–38% of the general population, more than 85% of the
patients with narcolepsy-cataplexy have the HLA DQB1*0602
allele, most often in combination with HLA-DR2 (DRB1*1501)
(Mignot, 1998). Moreover, the DQB1*0602 allele alone, particu-
larly when homozygous, was the major narcolepsy susceptibility
allele in different ethnic groups including African-Americans,
Caucasian-Americans and Japanese (Mignot et al., 2001).
Several alleles have been identified that appeared to be protective
(DQB1*0601, DQB1*0501 and DQA1*01) (Mignot et al., 2001).
Among genetic factors linked to autoimmune disease develop-
ment, MHC class II (MHCII) genes on chromosome 6 account for
the majority of cases of familial clustering in common autoimmune
diseases, and have also been linked to sporadic forms. In systemic
lupus erythematosus, the most consistent HLA associations are
with the MHCII allotypes, HLA-DR3 and HLA-DR2. A pre-eminent
role of the extended haplotype defined by HLA-DRB1*1501 has
also been highlighted in recent studies on multiple sclerosis
(Fernando et al., 2008). The mechanisms that account for
MHCII associated anti-self immunity remain poorly defined.
Tolerance to self-antigens is achieved by deletion of T cell precur-
sors that express T cell receptors (TCRs) having high avidity for
self-antigen—MHC complexes expressed on dendritic cells and
epithelial cells in the thymus. Peripheral immune tolerance mech-
anisms control mature T cells that bear a TCR of low avidity for
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self-antigen—MHC complexes and that escape from the thymus
to the periphery (Mueller, 2010). A commonly held view is that
disease-associated HLA allotypes promote a breach of peripheral
self-tolerance because they favour the presentation of specific
self-peptides to autoreactive T cells. Alternatively, the disease-
associated HLA allotypes could bias the TCR repertoire generated
during T cell development in the thymus towards the selection of
potentially pathogenic autoreactive specificities. It has also been
proposed that autoimmunity might be promoted by ectopic or
inappropriately high levels of HLA expression in the diseased tis-
sues. An intriguing observation has been provided by crystallo-
graphic studies using a soluble form of DQ0602 complexed with
a peptide from human hypocretin (amino acids 1–13) (Siebold
et al., 2004). The hypocretin peptide is presented in the
DQ0602-binding grove with peptide side chains anchored in the
P4 and P9 pockets. These pockets differ significantly between
the DQ0602 narcolepsy susceptibility molecule and DQ0601, an
allele that is protective. Since no anti-self immunity to hypocretin
has been detected so far, the significance of these studies
remains open.
The hallmarks of T cell involvement in autoimmune diseases
are the presence of T cells sensitized to self-antigens, dysregulated
effector CD4+ T cells, such as T helper 17 cells, low titres of
regulatory T cells, and inflammation at the sites of autoimmune
attack. The inflammatory reaction is typically characterized by a
local accumulation of CD4+ T cells and proinflammatory macro-
phages with increased expression of MHCII and cytokines. None
of these characteristic features of T cell autoimmunity have been
documented in narcolepsy. However, in a highly interesting recent
study on T cell receptor alpha (TCR) or -beta (TCRb) subtypes,
807 narcolepsy patients positive for HLA-DQB1*0602 and exhibit-
ing hypocretin deficiency in the CSF, as well as 1074 controls were
selected for a genome-wide association study. The data identified
an association between narcolepsy and polymorphisms in the
TCR locus. The TCR chain is part of the TCR of CD8+ T cells,
which recognize antigens presented by HLA class I molecules, and
CD4+ T cells, which recognize antigens presented by HLA class II
molecules, including the DQ (alpha) b (beta) heterodimer
denoted DQ 0602, which is encoded by the DQB1*0602 and
DQA1*0102 alleles. Somatic recombination in the TCR and
TCRb loci in developing T cells leads to the generation of a diverse
repertoire of distinct TCR b idiotype-bearing T cells. Since
narcolepsy is almost exclusively associated with a single HLA
allele—DQB1*0602—the authors suggest that the TCR poly-
morphism could contribute to autoimmunity directed against
hypocretin neurons by influencing the occurrence of variable-
joining region VJ2 recombinations that can interact with
DQ0602 (Hallmayer et al., 2009).
Another interesting observation has recently been described in a
series of experiments reported by Carla Shatz (2009). Since the
initial report of MHCI expression and activity regulation in
neurons, it has been suggested that altered MHCI expression con-
tributes to synaptic changes and learning defects (for review see
Shatz, 2009). In a search for MHCI-binding receptors, TCRb
mRNA was detected in neurons. However, TCR—the second
obligatory component of a functional TCR—was not detected in
neurons. As a hypothesis, polymorphism of the TCR-b genes may
influence the interaction with MHCI and thereby neuroprotection
in disease states (Boulanger and Shatz, 2004). Some support
for this comes from experiments with mice that lack either
b2-microglobulin—a cosubunit for MHCI—or the transporter asso-
ciated with antigen processing 1 (TAP1) required for loading
antigen peptides onto MHCI molecules. Sciatic nerve transsection
in both types of mutant mice showed axotomized -motoneurons
to have more extensive detachments of synapses than those in
wild-type mice (Oliveira et al., 2004). More sensitive techniques
to detect TCR and b gene expression and studies on TCR—MHCI
interactions on neurons are required to come to conclusions on the
significance of MHCI expression by neurons.
The strong association of narcolepsy with HLA-DQB1*0602 has
prompted interest in the hypothesis that narcolepsy is an auto-
immune disease. However, several issues relevant to this model
deserve emphasis.
(i) From a clinical point of view, a specific autoimmune disease
is often associated with various other autoimmune manifest-
ations in the affected individual or in the family of the
patient. Classical autoimmune diseases, such as systemic
lupus erythematosus, rheumatoid arthritis or myasthenia
gravis have not been reported to be increased in narcoleptic
patients or their families. In fact, other autoimmune diseases
(e.g. systemic lupus erythematosus, multiple sclerosis and
neuromyelitis optica with anti-aquaporin-4 antibodies) have
been observed only very rarely in narcoleptic patients
(Younger et al., 1991; Pablos et al., 1993; Baba et al.,
2009).
(ii) Unlike the situation observed in other autoimmune diseases,
including systemic lupus erythematosus, rheumatoid arthritis
and Sjo¨gren syndrome, associated autoantibodies such as
antinuclear antibodies, antibodies to nDNA, SS-A, Sm, his-
tone and rheumatoid factor are not increased in narcolepsy
(Rubin et al., 1988). It is of note that no data are provided
about the duration of the disease at the time point when the
sera were taken for the study.
(iii) Intrathecal synthesis of immunoglobulins and oligoclonal
bands are only rarely seen in the CSF of narcoleptic patients.
One study reported two out of 15 patients to have oligo-
clonal bands and one of these to have an increased IgG
index in the CSF. These patients had narcoleptic symptoms
for 7 and 33 years, respectively (Fredrikson et al., 1990). In
another study, four of 22 patients with narcolepsy showed
oligoclonal bands in the CSF. The disease duration was 8,
10, 12 and 30 years, respectively. Measurement of anti-
bodies to various viruses showed three patients to be
positive for the herpes simplex virus (two patients) or
cytomegalovirus (Schuld et al., 2004). The assays used are
not sensitive enough to detect the production of antibodies
to CNS antigens.
(iv) There is so far no evidence for the presence of antibodies to
hypocretin or hypocretin receptor in the disease and anti-
bodies to Tribbles homolog 2 (Trib2) which is expressed by
hypocretin producing neurons have been detected in only
14% of narcoleptic patients (see below).
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(v) Autopsy studies have not shown an accumulation of T or
B lymphocytes in the CNS, an influx of monocytes from the
blood or an activation of microglia in the tissue, at least not
at late time points of the disease (Table 1). The limited
availability of tissues and CSF at early time points of the
disease has hampered the search for autoantibodies and
the detection of oligoclonal bands in CSF.
(vi) Finally, systemic markers indicating inflammation, such as
increased blood sedimentation and elevated C-reactive
protein cannot be demonstrated. Since intravenous immuno-
globulins proved effective in the treatment of various
autoimmune diseases, it is interesting to look at the response
of this treatment in narcoleptic patients. Several single
observations point to beneficial effects when immunoglo-
bulins are administrated close to disease onset (Plazzi
et al., 2008). However, persistent improvements of narco-
leptic symptoms were not observed in four other patients as
recently reported (Valko et al., 2008). Taken together, these
clinical findings do not support a role for local or even
systemic autoimmunity in narcolepsy. Several of the afore-
mentioned issues will be discussed in more detail below.
Are anti-neuronal antibodies
involved?
Loss of hypocretin neurotransmission may be due to impaired
production and/or secretion of hypocretin by neurons, or result
from the loss of neurons that produce hypocretin. Several studies
have addressed the hypothesis that autoantibodies may lead to
alterations in the hypocretin system. An increased IgG index or
oligoclonal bands were detected infrequently in the CSF of
patients with narcolepsy (see above). Thus intrathecal synthesis
of autoantibodies by local plasma cells is not a uniform finding
of the disease (Fredrikson et al., 1990; Schuld et al., 2004).
Furthermore, recent studies have failed to detect specific antibo-
dies against hypocretin or hypocretin receptors (Black et al., 2005;
Tanaka et al., 2006). In these studies no data are provided in
regard to the time point of disease onset and sampling of the
sera. No antibodies to hypothalamic neurons became detectable
in the sera of 46 narcoleptic patients, the duration of illness being
23.6 10.6 years (Overeem et al., 2006). Likewise, antibodies to
hypothalamic neurons were documented in only one of 9 patients,
and the antibody epitope was not characterized (Knudsen et al.,
2007). Insulin-like growth factor binding protein 3, which is
expressed in hypocretin neurons and downregulated in narcolepsy,
has recently been identified as a potential new autoimmune
target. However, no anti-insulin-like growth factor binding protein
3 antibodies were detected in human sera or the CSF of patients.
Insulin-like growth factor binding protein 3 concentrations in
the CSF were not decreased (Honda et al., 2009b). A new IgG
antibody from patients with narcolepsy has been described to
interfere with smooth muscle contractions in mouse colon prepar-
ations (Jackson et al., 2008). The epitopes of the antibodies
detected in the assay remain unclear. Hypocretin is apparently
not expressed in the murine gut (Baumann et al., 2008).
In a most recent, elegant search for proteins, which are
expressed exclusively by hypocretin producing neurons, the
screening approach came up with Trib2. While further character-
ization showed that Trib2 is not only expressed by hypocretin
neurons, but also by other neurons, the study nevertheless
points to Trib2 being an autoantigen in patients with narcolepsy
(Cvetkovic-Lopes et al., 2010). Using the 28 C-terminal amino
acids of Trib2 in an ELISA assay, 20 (14%) of 143 narcoleptic
patients had antibody titres of more than 2 SD above the mean
titre of healthy controls. Only 2 (5%) out of 42 healthy controls
had such antibodies (42 SD). The anti-Trib2 antibody titres were
detected more often in the first year of disease onset.
Immunhistochemistry showed that antibodies recognize hypocretin
Table 1 Autoimmunity in narcolepsy?
References
Pro
Association with HLA-DR2/DQB1*0602 Langdon et al., 1984; Matsuki et al., 1992
Polymorphism in the TCR locus Hallmayer et al., 2009
Dysregulation of TNF/TNF receptor system Hohjoh et al., 2001a; Okun et al., 2004; Himmerich et al., 2006
Increased antibodies to streptolysin and to DNAseB Billiard et al., 1989; Aran et al., 2009
Anti-Trib2 antibodies Cvetkovic-Lopes et al., 2010
Contra
Only rare association with known autoimmune diseases in patients with
narcolepsy, or in their families (e.g. systemic lupus erythematosis,
multiple sclerosis)
Pablos et al., 1993; Baba et al., 2009
No autoantibodies to nuclear proteins (antinuclear antibodies,
anti-nDNA)
Rubin et al., 1988
Usually no increase in IgG index and no oligoclonal bands in CSF Fredrickson et al., 1990; Schuld, 2004
No narcolepsy specific antibodies (anti-neuronal, anti-hypocretin,
anti-hypocretin receptor)
Black et al., 2005; Tanaka et al., 2006
No signs of inflammation in autopsy studies and no elevation of
C-reactive protein
Aran et al., 2009; Honda et al., 2009a; Thannickal et al., 2009
No TNF gene expression in the CNS Peyron et al., 2000
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neurons in the mouse hypothalamus. However, the staining
pattern looks cytoplasmic, which raises the question if the auto-
antibody would reach its intracellular antigen—Trib2—in vivo.
Future studies should aim at (i) developing the ELISA system
further in order to find other intramolecular epitopes which
harbour more dominant B cell epitopes than the C-terminal part
of the Trib2 protein; (ii) testing for T cell responsiveness to Trip2
and (iii) investigating if mice immunized with Trib2 or injected with
anti-Trib2 antibodies will develop a narcolepsy-like disease. Of
note, three of five patients with uveitis have been identified to
have anti-Trib2 antibodies (Zhang et al., 2005). However, since
the first description, the functional significance of the antibody
detected in uveitis has not been further investigated.
Antibodies to intracellular antigens are common in old people
and in a variety of infections and autoimmune diseases. However,
these antibodies are not directly involved in causing disease. The
same holds true for many of the anti-neuronal antibodies that
characterize neurological paraneoplastic disorders. This contrasts
antibodies to voltage-gated potassium or calcium channels located
at nerve terminals, which may lead to limbic encephalitis and
paraneoplastic cerebellar degeneration, respectively (for review
see Dropcho, 2005). Limbic encephalitis may also be associated
with antibodies to N-methyl-D-aspartic acid receptors (Graus et al.,
2008). In a recent study on 38 patients with antibodies to the
onconeuronal protein Ma-2, five patients were identified with ex-
cessive daytime sleepiness, and low to undetectable hypocretin in
the CSF that may indicate hypothalamic dysfunction (Dalmau
et al., 2004). However, anti-Ma-2 autoantibodies were not
detected in patients with narcolepsy (n= 19), the mean duration
of illness being 9.7 8.3 years (Overeem et al., 2004). However,
the clinical spectrum of anti-neuronal antibodies may be much
broader. For example, the risk of Parkinson’s disease is increased
among women with autoimmune diseases including Graves’
disease, insulin-dependent diabetes and pernicious anaemia
(Rugbjerg et al., 2009). These data may indicate the presence of
autoantibodies to dopaminergic neurons.
Are there signs of
inflammation in the CNS
in narcolepsy?
In autoimmune diseases, histological examination frequently re-
veals cellular infiltrates consisting of lymphocytes, plasma cells
and macrophages in areas of tissue destruction. It is therefore of
importance to determine whether this is seen in narcolepsy. What
regions in the CNS should be analysed in depth? As outlined
above, special attention should be given to hypocretin-1 and -2
producing neurons in the hypothalamus, and to the hypocretin
projection fields. Since the disease does not reduce life expectancy,
histological examination of brains is hardly an available option. In
one patient having a hypocretin mutation, early onset narcolepsy
(age 6 months) and a long follow-up over many years, histological
analysis did not show ‘obvious lesions’ and the presence of a mild
astrogliosis in the perifornical area remains controversial (Honda
et al., 2009a, Thannickal et al., 2009). Most importantly,
immunohistochemical staining of HLA-DR revealed normally dis-
tributed resting microglia in both the white and grey matter of
two narcoleptic subjects. Neither of the cases (aged 77 and 67
years) was associated with activated, amoeboid microglia. This is
remarkable, since the upregulation of HLA-DR expression and
microglia activation are hallmarks of immune-mediated inflamma-
tion in the CNS. In the context of a description of dysregulated
tumour necrosis factor (TNF) expression (see below) it is interest-
ing to note that in situ hybridization for TNF RNA did not reveal a
significant signal in control and narcoleptic tissue (Peyron et al.,
2000). Taken together, these findings do not support the model
that T cells and macrophages induce a reduction in the numbers of
hypocretin neurons. However, altered MHCI, MHCII and TNF
expression may only be seen early on, at the time of the loss of
hypocretin neurons, but not years after onset of disease.
Are TNF-a and its receptors
critical for the pathogenesis
of narcolepsy?
A growing body of evidence supports a role of the cytokine TNF-
in sleep disorders, including narcolepsy, fatigue in infectious and
autoimmune diseases and in sleep apnoea. TNF is a homotrimeric
cytokine that binds to two receptors, TNF receptor 1 and TNF
receptor 2. TNF is synthesized as a type-2 transmembrane protein
that is inserted into the membrane as a homotrimer and cleaved
by the matrix metalloprotease TNF- converting enzyme (ADAM
17) to a 51 kDa soluble circulating trimer (Idriss and Naismith,
2000). Both membrane-bound and soluble forms are mainly pro-
duced by monocytes, macrophages and dendritic cells. In the con-
text of sleep disorders, it is of note that TNF is produced in the
CNS, mainly by microglia cells and astrocytes, but also by neurons
(Frei et al., 1989; Lieberman et al., 1989; Probert and Akassoglou,
2001). TNF binds to TNF receptors 1 and 2, which are membrane
glycoprotein receptors. TNF receptor 1 is expressed on all types of
cells and binds membrane-bound TNF as well as soluble TNF. This
contrasts with TNF receptor 2, which is mainly expressed on cells
of the immune system, including microglia, and by endothelial
cells, and which binds only membrane-bound TNF (Wajant
et al., 2003). TNF is a pleiotropic inflammatory cytokine that
acts on parenchymal cells in various organs, including the CNS,
in which it modulates the functions of microglia, oligodendrocytes,
astrocytes and neurons. With respect to sleep disorders it is
of note that TNF alters glutaminergic transmission and synaptic
plasticity and scaling. TNF increases -amino-3-hydroxyl-
5-methyl-4-isoxazole-propionate (AMPA) receptors on neurons
and leads to inhibition of the expression of GABAA receptors,
which together leads to increased excitatory synaptic transmission
(Campbell and Trowsdale, 1993; Beattie et al., 2002; Stellwagen
et al., 2005; Stellwagen and Malenka, 2006). The TNF locus is
situated within the Class III region of the human MHC complex on
chromosome 6p21. In light of the association of narcolepsy with
HLA-DQB1*0602 it is interesting to study the expression of this
cytokine in narcoleptic patients.
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Interleukin-1b, interleukin-1 receptor antagonist, interleukin-2,
TNF and lymphotoxin-alpha in plasma and in mitogen-stimulated
monocytes and lymphocytes were not found to differ between
narcolepsy patients and HLA-DR2 matched control subjects
(Hinze-Selch et al., 1998). Only interleukin-6 was found to be
increased in lipopolysaccharide activated monocytes in narcolepsy.
However, increased TNF and interleukin-6 serum levels compared
to age- and gender-matched controls were detected in a later
study by Okun et al. (2004), who found the TNF concentration in
patients’ sera to be 13.9 1.39 pg/ml (control: 8.2 0.45 pg/ml)
and the interleukin-6 concentrations to be 6.7 1.45 pg/ml
(control: 0.49 0.09 pg/ml for IL-6) (Okun et al., 2004). In
the latter study, stimulatory drugs were associated with lower
TNF levels. As outlined above, genetic polymorphism in the
Tnf promoter may also influence TNF serum concentrations.
The TNF allele with the C-857T polymorphism was strongly asso-
ciated in the subgroup of DRB1*15/16 (HLA-DR2 type) negative
patients (Wieczorek et al., 2003). In a recent, well controlled
study, new information was obtained by Himmerich et al.
(2006). Whereas serum TNF was not increased, narcoleptic
patients had higher soluble TNF receptor 2 (but not soluble
TNF receptor 1) compared to controls. This may be explained
by genetic polymorphisms. Positive correlations have been
observed for the TNF (-857T) and TNF receptor 2 (-196T) com-
bination with narcolepsy, and for DRB1*1501 and TNF (-857T)
(Hohjoh et al., 2001a, b). Further studies should address the
relationship between soluble TNF receptor 2 and HLA-DR2.
Collectively, there is evidence that TNF and soluble TNF recep-
tor serum concentrations are abnormal in patients with narcolepsy
and that there are Tnf and TNF receptor 2 gene polymorphisms
that are linked to the HLA-DQB1*0602 allele. It is of note,
however, that the TNF promoter -857T allele, which correlated
with the presence of the TNF receptor 2 -196T allele in narco-
lepsy, has been found to be associated with an almost twice as
high TNF produced by blood mononuclear cells (Hohjoh and
Tokunaga, 2001c). Elevated plasma levels of soluble TNF receptor
2 have not only been detected in narcolepsy, but also in inflam-
matory diseases including rheumatoid arthritis (Glossop et al.,
2005). The extent of production of membrane-bound TNF, soluble
TNF and TNF receptor in the hypothalamus at onset of disease has
not yet been explored. It is open whether production of TNF and
TNF receptor 2 follows activation of MHCII expressing cells and
neurons, or follows tissue injury (Knoblach et al., 1999).
The studies on narcolepsy outlined above are also intriguing
because subcutaneous infusion of TNF impairs locomotor activity
in mice and lowers the expression of clock genes in the liver. TNF
acts on clock genes that are regulated by E-boxes in their
promoters—namely the PAR bZip clock controlled genes Dbp,
Tef and Hlf and the period genes Per1, Per2 and Per3—but not
Clock nor Bmal1, which lack E-boxes in their regulatory DNA
regions (Cavadini et al., 2007). Since clock genes are central in
the sleep-wake cycle and map to mouse chromosome 5 within a
region syntenic to human chromosome 4g12, a region close to the
narcolepsy susceptibility locus 4p/3-q21 identified recently, poly-
morphisms have been analysed in the Clock gene (Nakayama
et al., 2000). However, no differences in allelic and genotypic
frequencies of two clock polymorphisms have been observed in
narcolepsy compared to controls (Moreira et al., 2005).
Death of hypocretin expressing
neurons in narcolepsy from an
immunological point of view
Taking into account the immunological features of narcolepsy
outlined above (HLA-DQB1*0602 association, polymorphisms in
the TNF/TNF receptor genes and in the TCR locus, anti-Trib2
antibodies), death of hypocretin neurons in narcolepsy could be
immune mediated. T cell cytotoxicity mediated by MHCI restricted
neuronal killing is unlikely. Antigen-specific lysis of target cells
by cytotoxic CD8+ T cells requires expression of MHCI antigens
(Walter and Santamaria, 2005). However in the normal CNS,
these molecules are not expressed, or only at low levels, in
synapses and dendrites of neurons (Goddard et al., 2007). The
induction of MHCI molecules and b2-microglobulin also depends
on membrane depolarization (Neumann et al., 1995; Rensing-Ehl
et al., 1996). In autoimmune and viral diseases of the CNS there is
still no convincing evidence for MHCI-dependent killing of neu-
rons by CD8+ T cells. The sensitivity of neurons to cytotoxic CD8+
T cell-mediated killing has only been demonstrated convincingly
with neurons transfected with a gene encoding an MHC class I
molecule (Joly et al., 1991; Rall et al., 1995).
MHCII molecules such as HLA-DR2 and HLA-DQB1*0602 bind
(self) antigens and interact with antigen-specific TCRs on CD4+
T cells (Chen et al., 2009). MHCII in the CNS is only expressed by
microglia and by blood derived monocytes, perivascular macro-
phages and dendritic cells. These cells may activate invading
CD4+ T cells in an antigen and MHCII dependent manner.
However, autoptic studies in narcolepsy have detected neither
T cells nor increased MHCII expression in the hypothalamus.
Since these studies were performed with tissues from patients
with long lasting disease, it cannot be excluded that the picture
might be very different at the onset of narcolepsy. CD4+ T cells
may recognize bacterial antigens, e.g. streptococcal antigens
and/or self-antigens. The latter could be a consequence of
molecular mimicry between host and pathogen as shown for
example in post-streptococcal Sydenham chorea (Kirvan et al.,
2003). Patients with narcolepsy (n= 200), that are characterized
by being DQB1*0602 positive and low hypocretin in the CSF,
have recently been found to have increased antibodies to strepto-
lysin and to DNAseB within the first 3 years after onset of disease
when compared to age-matched controls (n= 200) (Aran et al.,
2009). C-reactive protein levels were not increased. Antibodies to
streptolysin and antibodies to DNAseB titres were highest close to
narcolepsy onset, and decreased with disease duration. This
contrasts with anti-Helicobacter pylori antibodies, which did not
differ from controls. Clinical studies showed that the risk of
narcolepsy in a person with a history of a physician-diagnosed
streptococcal throat infection before age 21 was 5.4-fold higher
than in individuals without such a history (Longstreth et al., 2009).
Twenty years ago, increased streptolysin and DNAseB antibody
titres were observed in a small number of narcoleptic patients,
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although this finding was not reproduced later (Billiard et al.,
1989; Mueller-Eckhardt et al., 1990). Group size and the time
interval between onset of disease and blood testing may contrib-
ute to differences in the data.
Immune-mediated bystander
killing of neurons
In narcolepsy, the loss of neurons is very selective and includes
neurons expressing hypocretin-1, but not neighbouring neurons
that produce melanin-concentrating hormone (Blouin et al.,
2005; Thannickal et al., 2009). Selectivity could be due to neuro-
toxic autoantibodies binding to unique antigens expressed only by
hypocretin neurons. However, such antibodies have not been
detected so far (see above).
Because neurons express only low levels of MHCI/II, T lympho-
cytes are unlikely to interact in an antigen-dependent way with
neuronal cells. However, T cell-mediated killing of neurons could
be indirect, neurotoxicity being due to T cell-mediated bystander
killing. For example, CA1 hippocampal neurons expressing a trans-
gene encoding the nucleoprotein of Borna disease virus showed
no damage when mice were injected with Borna disease
virus-specific CD8+ T cells (Richter et al., 2009). This contrasts
with mice expressing the nucleoprotein of Borna disease virus in
astrocytes. In this situation, Borna disease virus-specific CD8+
T cells were found to interact with regional nucleoprotein positive
astrocytes and thereby caused collateral damage to uninfected
CA1 neurons. This effect was thought to be the result of neuro-
toxic molecules released from functionally impaired astrocytes
(Richter et al., 2009). Using glutamate receptor antagonists,
death of uninfected hippocampal CA1 neurons due to glutamate
receptor overstimulation was excluded. The authors suggest that
the interaction of CD8+ T cells with astrocytes may impair
astrocyte-mediated detoxification of potentially neurotoxic
molecules or the production of neurotrophic factors by astrocytes
(Richter et al., 2009). Likewise, anti-self CD8+ T cells may cause
bystander toxicity by acting on astrocytes expressing MHCI, the
cellular interaction causing death of hypocretin neurons. Bystander
neurotoxicity has also been observed to develop in the course of
the generation of cytotoxic CD8+ T cells that recognize virus
(e.g. JC virus) infected MHCI positive oligodendrocytes (for
review see Melzer et al., 2009). Another example of bystander
neurotoxicity is provided by studies using ovalbumin-specific
CD4+ T cells. These cells lead to a lethal MHCII- and
antigen-independent increase in neuronal calcium, which could
be prevented by blocking glutamate receptors and perforin
(Nitsch et al., 2004).
Neurotoxicity by CD4+ T cells may either be mediated by their
release of neurotoxic molecules, including interferon gamma
(IFNg), TNF and lymphotoxin  or be due to their ability to acti-
vate microglia to produce the aforementioned cytokines, as well
as radical oxygen intermediates, nitric oxide and glutamate
(Fig. 1) (Piani et al., 1992). TNF by itself is capable of inducing
largely unselective, high-conductance ion channels following
pH-dependent insertion into lipid bilayer or cell membranes
(Kagan et al., 1992; Baldwin et al., 1996). It is interesting
that in rat hypothalamic slice cultures the addition of
N-methyl-D-aspartate resulted in a marked decrease in the
number of hypocretin neurons, whereas neurons expressing
melanin-concentrating hormone were relatively spared (Katsuki
and Akaike, 2004). Quinolinic acid, a tryptophan metabolite
produced by the kynurenine pathway, possesses an agonist
activity on N-methyl-D-aspartic acid receptors and leads to select-
ive loss of hypocretin neurons. Microglia cells and blood-derived
monocytes/macrophages are prominent sources of quinolinic acid
(Stone, 2001). Hypocretin neurons express N-methyl-D-aspartic
acid receptors, the glutaminergic inputs regulating their electrical
activity (Li et al., 2002). In contrast to neurons expressing
melanin-concentrating hormone, hypocretin neurons are inhibited
by elevation of extracellular glucose, the effect being mediated
by two pore potassium (K2P) channels (Burdakov et al., 2006).
Differences of melanin-concentrating hormone neurons and hypo-
cretin neurons, which may result in selective killing of hypocretin
neurons, may also depend on ectopic expression of death recep-
tors including TNF receptor or Fas, or a high degree of sensitivity
towards proapoptotic signals. The latter may be due to the ab-
sence of anti-apoptotic intracellular molecules or of neuroprotec-
tive factors or their receptors. Regulation of apoptosis is central
in the neuroprotection and neurodegeneration (Okouchi et al.,
2007).
To assess T cell autoimmunity in narcolepsy, further work should
examine (i) whether there is a restricted usage of TCR genes;
(ii) whether T cell activation and neurotoxic effects of T cells
from patients are observed in co-cultures with immortalized hypo-
thalamic neurons transfected with HLA-DR2 genes; (iii) whether
signs of narcolepsy develop in humanized severe combined
immunodeficiency mice that express human HLA-DR2 genes
and are injected with reactivated CD4+ T cells from narcoleptic
patients; and (iv) whether monoclonal antibodies with streptococ-
cal reactivity can induce apoptosis of hypocretin neurons in vitro.
Superantigen-induced T cell
activation and neurotoxicity
An alternative model is that infectious pathogens in the hypo-
thalamus may express superantigens that bridge the TCR on
T cells with MHCII molecules expressed by cells such as microglia.
Bacterial or viral superantigens concentrate on the surface of
antigen presenting cells by binding to MHCII molecules and
then engage and crosslink multiple TCR molecules, resulting in
strong TCR signalling, T cell activation and cytokine production.
IFN-g released by superantigen activated T cells may lead to
neuronal excitotoxicity by intracellular trans-signalling between
the IFN-g receptor and a Ca2+- permeable neuronal -amino-
3-hydroxyl-5-methyl-4-isoxazole-propionate/kainate receptor in
the absence of extracellular glutamate (Mizuno et al., 2008).
As a hypothesis, the narcolepsy associated polymorphism of the
TCR locus, as well as DQB1*0602 on cells such as microglia,
might permit only a limited engagement of the TCR in the
superantigen-dependent process, and thereby cause only minimal
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Figure 1 Autoantibody, T lymphocyte and microglia induced killing of hypocretin neurons. (1) Hypocretin neurons may be destroyed by
autoantibodies such as Trib2 (Cvetkovic-Lopes et al., 2010) which are produced by B cells. (2) Priming of CD4+ T cells to self-antigens
presented to TCR by DQB1*0602 expressing antigen presenting cells (APC) including dendritic cells, monocytes, macrophages and
microglia cells leads to activation of B cells and of antigen presenting cells. The latter produce neurotoxic factors such as quinolinic acid,
glutamate, radical oxygen intermediates (ROI) and TNF- (Katsuki and Akaike, 2004). (3) Since the significance of the expression of MHCI
(Continued)
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inflammation (Fig. 1). A stronger interaction would be inconsistent
with the limited pathology and destruction of only one type of
cell—the hypocretin neurons in the hypothalamus. Most superan-
tigens interact with TCR molecules by binding primarily to the
variable region of the b chain (for review: Fraser and Proft,
2008). It might thus seem unlikely that the recently observed
polymorphism in the TCR locus could reflect the involvement
of superantigens in narcolepsy. However, there are also superanti-
gens that bind to alpha chains of the TCR. The staphylococcal
toxin staphylococcal enterotoxin H recognizes the variable region
of the TCR-chain (V27) (Pumphrey et al., 2007) and the myco-
plasma arthritidis mitogen consists of two -helical bundles, one of
which binds orthogonally to the top of the MHCII1-helix, peptide
and b1-helix (Zhao et al., 2004).
T cell-independent
MHCII-mediated neurotoxicity
In T cell-mediated diseases of the CNS, such as multiple sclerosis
or experimental autoimmune encephalomyelitis, the function of
MHCII is primarily that of antigen presentation by microglia and
macrophages. However, in conditions such as Huntington’s dis-
ease and Parkinson’s disease, or brain trauma, the aforementioned
types of cells express MHCII despite the fact that no evidence for
T cell involvement has been observed. In these diseases, upregula-
tion of MHCII in microglia cells may follow the ingestion of
apoptotic cells (Hellendall and Ting, 1997). Necrotic neurons
have been shown to activate microglia to upregulate MHCII, cost-
imulatory molecules CD40, CD24, b2 integrin, CD11b, inducible
nitric oxide synthetase and cytokines including TNF (Pais et al.,
2008). It has been suggested that an alternative role for MHCII
might involve signal transduction leading to activation, differenti-
ation and production of proinflammatory cytokines. Cuprizone-
induced oligodendrocyte dysfunction with T cell-independent
demyelination pathology is much less pronounced in MHCII
I  A=ðbetaÞmice, or in mice expressing a truncated I-A(beta) chain
lacking a cytoplasmic domain. It is not clear yet how signalling by
MHCII molecules is activated in the absence of T cell function
(Matsushima et al., 1994; Hiremath et al., 2008). These findings
may be of relevance for narcolepsy. As a hypothesis, infectious
pathogens may have a tropism for hypothalamic hypocretin neu-
rons and thereby cause these neurons to activate microglia to
increase signalling via their MHCII molecules (Fig. 1). Activated
microglia induce neurotoxicity by releasing quinolinic acid or
through the upregulation of glutaminase, an enzyme that pro-
duces the N-methyl-D-aspartic acid receptor agonist glutamate
(Piani et al., 1991, 1992; Pais et al., 2008). The activation of
microglia by necrotic neurons was shown to be dependent on
the toll-like receptor-associated adaptor molecule myeloid differ-
entiation primary response gene (MyD88).
Conclusion
Autoimmunity, superantigen-mediated T cell activation and
non-T cell-mediated activation by MHCII signalling could be
involved in narcolepsy. Whereas HLA-DQB1*0602 might select
for recognition of self-antigens and thereby lead to autoimmunity,
the polymorphism of the TCR (alpha) gene might be crucial
in superantigen-mediated T cell activation. The existence of
CD8+-mediated neuronal cell death has not yet been convincingly
proven in vivo. However, CD8+ induced damage of MHCI
expressing astrocytes or oligodendrocytes may be followed by
collateral toxicity to neurons. HLA-DQB1*0602 might be more
vulnerable to T cell-independent, MHCII-mediated activation of
macrophages and microglia. These cells have been shown to
release neurotoxic molecules including Fas ligand, proteases,
TNF, quinolinic acid, glutamate, radical oxygen intermediates
and nitric oxide. Selectivity of killing of hypocretin neurons may
be due to a high degree of sensitivity towards the aforementioned
cytotoxic molecules as has been shown with quinolinic acid. The
detection of an increased frequency of streptococcal infection in
narcolepsy may provide a hint for molecular mimicry and auto-
immunity or for the involvement of superantigens as initiators of
T cell activation. For the detection of anti-CNS antibodies and
activation of T cells/monocytes in the blood, future studies
should concentrate on patients with a newly diagnosed or very
recent onset of disease.
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Figure 1 Continued
molecules on neurons in vivo is still a matter of debate, the contribution of CD8+ T cell-mediated killing of neurons remains open.
However there is evidence for CD8+ T cell-mediated antigen-dependent interaction with MHCI expressing astrocytes (A) or oligo-
dendrocytes (O) which as reported may result in damage of these glial cells and collateral toxicity of neurons (Melzer et al., 2009; Richter
et al., 2009). (4) Neurotoxic molecules may also be released by antigen presenting cells that bind bacterial or viral superantigens via MHCII
molecules. Crosslinking of TCRs on T cells leads to release of neurotoxic molecules including interferon gamma (IFN-g) and TNF. (5)
Activation of microglia cells or other antigen presenting cells including dendritic cells and monocyte derived macrophages may also be
mediated by signalling through MHCII molecules in the absence of T cells (Matsushima et al., 1994; Hiremath et al., 2008). The ligand,
which binds to MHCII as well as the origin of the ligand (hypocretin neurons?), are not known. MHCII-mediated activation of antigen
presenting cells leads to the release of neurotoxic molecules.
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